IMPACT Therapeutics, Inc

南京英派药业股份有限公司

07630.HK

Develops synthetic lethality-based precision anti-cancer therapies, with commercialized senaparib for first-line maintenance therapy in ovarian cancer in China; pipeline includes ADCs and degraders, with partnerships with global biotech and China pharmaceutical companies.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Key long-term agreements
• Cash burn and runway
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Contract liabilities and customer prepayments
• Chapter 18A biotech